Neion Bio’s core product is the Raptor™ platform, which leverages genetic engineering to restrict recombinant protein production to chicken eggs as a means to manufacture complex, glycosylated biologic proteins. Founded in 2024, the company is positioning the platform to address scalability, resiliency, capital efficiency, speed, and the ability to express difficult-to-manufacture molecules. Neion plans to expand its pipeline across biosimilars, innovative medicines, critical reagents, and animal health and to commercialize via partnerships, including a recently announced multi-product biosimilars co-development and supply agreement with a major pharmaceutical company. The company is advancing proprietary technologies intended to enable production at meaningful scale within days and to shorten iteration cycles for molecule screening and production. Financially, Neion completed an oversubscribed $23 million Series A to fund these platform and pipeline initiatives.

Total raised

$34M

Funding rounds

2

Latest round

Series A

Latest activity

Jun 2026